Deutsche Labs Inc.

Deutsche Labs Inc. is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered at 304 Sammani 11, Opposite Shell Petrol Pump, Satellite, Ahmedabad, Gujarat, India. The Corporate Identification Number (CIN) for Deutsche Labs Inc. is 26IN0805006362. (en.nbd.ltd) While specific revenue figures are not publicly disclosed, the company has demonstrated a consistent export performance, with a total export value of $437,000 USD across 15 shipments from 2022 to 2026. The workforce comprises approximately 20 employees, reflecting a focused operational structure. The company's official website is not publicly available.

Deutsche Labs Inc. operates manufacturing facilities in Ahmedabad, Gujarat, India. Specific details regarding plant capacities and specializations are not publicly disclosed. The company's export data indicates a focus on finished pharmaceutical formulations, suggesting that its manufacturing facilities are equipped to produce a range of dosage forms, including tablets, capsules, syrups, and injections. However, without publicly available information, a detailed assessment of manufacturing capacities and specializations cannot be provided.

The key leadership of Deutsche Labs Inc. includes Michael Robinson, who serves as the President and Chief Executive Officer (CEO). Specific information regarding other executive roles, such as Chief Financial Officer (CFO) or Chief Operating Officer (COO), is not publicly available. The company's leadership appears to be centralized, with a focus on strategic decision-making at the top level.

Deutsche Labs Inc. has engaged in export activities to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to destinations such as the United States, with records of shipments arriving at ports like New York/Newark Area, Newark, New Jersey. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed. The absence of publicly available information on regulatory approvals suggests that Deutsche Labs Inc. may not have established formal market access in these regulated markets.

Deutsche Labs Inc. has demonstrated export activities to emerging markets, including regions in Africa, Latin America, and Southeast Asia. For instance, the company has engaged in shipments to countries such as Guinea and Venezuela. While these activities indicate a presence in emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available. The lack of publicly disclosed information on such certifications suggests that Deutsche Labs Inc. may not possess WHO prequalification or similar certifications for its products.

Deutsche Labs Inc. exhibits a diversified geographic strategy, engaging in export activities across multiple regions, including North America, Europe, Africa, Latin America, and Southeast Asia. This diversification indicates a strategic approach to mitigate risks associated with over-reliance on a single market. However, the absence of publicly available information on regulatory approvals and certifications in these regions suggests that the company may face challenges in establishing formal market access. The lack of such certifications could impact the company's ability to fully capitalize on opportunities in these markets.

Specific details regarding Deutsche Labs Inc.'s FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The absence of such information suggests that the company may not have established formal approvals or registrations with the U.S. Food and Drug Administration (FDA). This lack of FDA approvals could limit the company's ability to market its products in the United States.

There is no publicly available information indicating that Deutsche Labs Inc. holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The absence of such certifications suggests that the company may not have undergone the necessary evaluations to meet these international standards. This lack of certification could affect the company's ability to access certain international markets that require such approvals.

Specific details regarding Deutsche Labs Inc.'s manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly available. The absence of such information suggests that the company may not have obtained formal regulatory approvals from Indian authorities. This lack of regulatory approvals could impact the company's ability to operate within India and export products internationally.

There is no publicly available information indicating that Deutsche Labs Inc. has received FDA Form 483 observations, warning letters, or import alerts. Similarly, there is no information regarding any regulatory actions from other authorities such as the WHO, EU, or CDSCO. The absence of such information suggests that the company may not have been subject to recent regulatory scrutiny or enforcement actions.

Deutsche Labs Inc. operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors are not publicly identified, the company's export data indicates engagement with various international buyers, including those in the United States, Europe, and Africa. The lack of publicly available information on regulatory approvals and certifications may place the company at a competitive disadvantage compared to peers with established market access and recognized quality standards.

Deutsche Labs Inc. specializes in finished pharmaceutical formulations, offering a range of dosage forms such as tablets, capsules, syrups, and injections. The company's export data indicates a focus on specific therapeutic categories, including advanced antibiotics, tuberculosis medications, and antimalarial & antiparasitic drugs. However, the absence of publicly available information on regulatory approvals and certifications suggests that the company may face challenges in differentiating itself in markets that require such credentials.

Deutsche Labs Inc. appears to focus on the export of generic pharmaceutical formulations, with an emphasis on specific therapeutic areas. The company's strategic direction may involve expanding its product portfolio and exploring new markets. However, the lack of publicly available information on regulatory approvals and certifications suggests that the company may need to invest in obtaining necessary credentials to enhance its strategic position and access additional markets.

Deutsche Labs Inc. has demonstrated a consistent export performance, with a total export value of $437,000 USD across 15 shipments from 2022 to 2026. The company's export data indicates shipments to various international buyers, including those in the United States, Europe, and Africa. However, the absence of publicly available information on regulatory approvals and certifications suggests that the company may face challenges in establishing itself as a reliable supplier in markets that require such credentials.

Importers should verify the following certifications when considering Deutsche Labs Inc. as a supplier:

• FDA Facility Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration.

• WHO Prequalification: Ensure that products meet the World Health Organization's prequalification standards.

• EU GMP Certification: Verify that manufacturing processes comply with European Union Good Manufacturing Practice standards.

• CDSCO Manufacturing License: Check that the company holds a valid manufacturing license from the Central Drugs Standard Control Organisation.

To verify these certifications, importers can request copies of the certificates directly from Deutsche Labs Inc. or consult the respective regulatory bodies' official databases.

When conducting due diligence on Deutsche Labs Inc., consider the following steps:

• Regulatory Compliance: Verify that the company holds necessary certifications and approvals from relevant regulatory bodies.

• Quality Assurance: Assess the company's adherence to international quality standards and manufacturing practices.

• Financial Stability: Review financial statements to evaluate the company's financial health and stability.

• Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain and delivery timelines.

• References and Reviews: Seek feedback from previous clients and partners to gauge the company's reputation and reliability.

Red flags to watch for include a lack of verifiable certifications, inconsistent product quality, financial instability, and negative feedback from previous clients. Recommended pre-order checks involve requesting product samples, reviewing quality control processes, and confirming delivery schedules.